Arvinas, Inc.
corporate_fare Company Profile
Arvinas, Inc. (NASDAQ:ARVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ARVN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ARVN spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Arvinas 10-Q: $558.9M Cash Funds Operations Into 2H 2028 After $53.9M Q3 Loss
- Arvinas Posts $0.82 Q3 Loss as Revenue Collapses to $0.5M; Cash Runway to 2H 2028
- Arvinas Posts 82-Cent Quarterly Loss as Profitability Fades
- Arvinas' ARV-102 Shows Oculomotor and Biomarker Improvements in Parkinson's Phase 1
- Arvinas Doses First Patient in Phase 1/2 Trial of First-in-Class HPK1 Degrader
Financial Snapshot
Short Interest & Short Volume
7.59 days to coverFINRA reported short interest of 5,751,346 shares in ARVN as of the October 30, 2026 settlement, a 2.8% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 68.9% of ARVN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ARVN, detected from its recent SEC filings.
New $400M Shelf Registered · $200M At-The-Market Program
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →